Safety profile of cyclin-dependent kinase (CDK) 4/6 inhibitors with concurrent radiation therapy: A systematic review and meta-analysis.
Date
2023-09-01ICR Author
Author
Becherini, C
Visani, L
Caini, S
Bhattacharya, IS
Kirby, AM
Nader Marta, G
Morgan, G
Salvestrini, V
Coles, CE
Cortes, J
Curigliano, G
de Azambuja, E
Harbeck, N
Isacke, CM
Kaidar-Person, O
Marangoni, E
Offersen, B
Rugo, HS
Morandi, A
Lambertini, M
Poortmans, P
Livi, L
Meattini, I
Type
Journal Article
Metadata
Show full item recordAbstract
The cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) have become the standard of care for hormone receptor-positive (HR + ) and human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer, improving survival outcomes compared to endocrine therapy alone. Abemaciclib and ribociclib, in combination with endocrine therapy, have demonstrated significant benefits in invasive disease-free survival for high-risk HR+/HER2- early breast cancer patients. Each CDK4/6i-palbociclib, ribociclib, and abemaciclib-exhibits distinct toxicity profiles. Radiation therapy (RT) can be delivered with a palliative or ablative intent, particularly using stereotactic body radiation therapy for oligometastatic or oligoprogressive disease. However, pivotal randomized trials lack information on concomitant CDK4/6i and RT, and existing preclinical and clinical data on the potential combined toxicities are limited and conflicting. As part of a broader effort to establish international consensus recommendations for integrating RT and targeted agents in breast cancer treatment, we conducted a systematic review and meta-analysis to evaluate the safety profile of combining CDK4/6i with palliative and ablative RT in both metastatic and early breast cancer settings.
Collections
Subject
Breast cancer
CDK4/6 inhibitors
Meta-analysis
Radiotherapy
Systematic review
Toxicity
Humans
Female
Radiosurgery
Breast Neoplasms
Cyclin-Dependent Kinases
Cyclin-Dependent Kinase 4
Protein Kinase Inhibitors
Cyclin-Dependent Kinase 6
Antineoplastic Combined Chemotherapy Protocols
Research team
Molecular Cell Biology
Language
eng
Date accepted
2023-06-10
License start date
2023-09-01
Citation
Cancer Treatment Reviews, 2023, 119 pp. 102586 -
Publisher
ELSEVIER SCI LTD
Except where otherwise noted, this item's license is described
as
http://creativecommons.org/licenses/by/4.0/
Related items
Showing items related by title, author, creator and subject.
-
A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours.
Jamieson, D; Griffin, MJ; Sludden, J; Drew, Y; Cresti, N; et al. (ELSEVIER SCI LTD, 2016-11-01)PURPOSE: We performed a multi-centre phase I study to assess the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the orally available small molecule mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor, ... -
Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.
Whittaker, SR; Cowley, GS; Wagner, S; Luo, F; Root, DE; et al. (AMER ASSOC CANCER RESEARCH, 2015-12-01)RAF and MEK inhibitors are effective in BRAF-mutant melanoma but not in BRAF-mutant colorectal cancer. To gain additional insights into this difference, we performed a genome-scale pooled shRNA enhancer screen in a ... -
Ubiquitin-Mediated Regulation of RIPK1 Kinase Activity Independent of IKK and MK2.
Annibaldi, A; Wicky John, S; Vanden Berghe, T; Swatek, KN; Ruan, J; et al. (CELL PRESS, 2018-02-15)Tumor necrosis factor (TNF) can drive inflammation, cell survival, and death. While ubiquitylation-, phosphorylation-, and nuclear factor κB (NF-κB)-dependent checkpoints suppress the cytotoxic potential of TNF, it remains ...